Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1684/ecn.2020.0448

http://scihub22266oqcxt.onion/10.1684/ecn.2020.0448
suck pdf from google scholar
32933891!7530350!32933891
unlimited free pdf from europmc32933891    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32933891      Eur+Cytokine+Netw 2020 ; 31 (2): 44-49
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Interleukin-6 and severe COVID-19: a systematic review and meta-analysis #MMPMID32933891
  • Mojtabavi H; Saghazadeh A; Rezaei N
  • Eur Cytokine Netw 2020[Jun]; 31 (2): 44-49 PMID32933891show ga
  • BACKGROUND: Evidence links COVID-19 severity to hyper-inflammation. Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was shown to lead to clinical improvement in patients with severe COVID-19. We, therefore, performed the present systematic review and meta-analysis to investigate whether the circulating levels of IL-6 is a reliable indicator of disease severity among patients affected with COVID-19. METHODS: A systematic search was conducted in PubMed, Scopus, Web of Science, and Google Scholar on April 19, 2020. RESULTS: Eleven studies provided data of IL-6 levels in patients with severe to critical COVID-19 (severe) and patients with mild to moderate COVID-19 (non-severe). The included studies were of moderate to high quality. The mean patients' age was 60.9 years, ranging from 45.2 to 76.7 years in the severe group and 46.8 years, ranging from 37.9 to 61 years, in the nonsevere group. Fifty-two percent were male in the severe group, as compared to 46% in the non-severe group. An overall random effects meta-analysis showed significantly higher serum levels of IL-6 in the severe group than in the non-severe group with a mean difference of +23.1 pg/mL (95% CI: 12.42-33.79) and the overall effect of 4.24 (P-value < 0.001). Meta-regressions showed that neither age nor sex significantly influenced the mean difference of IL-6 between the groups. CONCLUSIONS: Meta-analysis and meta-regression reveal a reliable relationship between IL-6 and COVID-19 severity, independent of age and sex. Future research is, however, required to assess the effect of BMI on the pattern of IL-6 production in patients with COVID-19. Also, there might be confounding factors that influence the relationship between IL-6 and COVID-19 severity and remain as yet unknown.
  • |Aged[MESH]
  • |Anti-Inflammatory Agents/*therapeutic use[MESH]
  • |Antibodies, Monoclonal, Humanized/*administration & dosage[MESH]
  • |Antiviral Agents/*therapeutic use[MESH]
  • |Betacoronavirus/*immunology/pathogenicity[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/*drug therapy/immunology/mortality/virology[MESH]
  • |Cytokine Release Syndrome/*drug therapy/immunology/mortality/virology[MESH]
  • |Female[MESH]
  • |Gene Expression[MESH]
  • |Humans[MESH]
  • |Intensive Care Units[MESH]
  • |Interleukin-6/*antagonists & inhibitors/genetics/immunology[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*drug therapy/immunology/mortality/virology[MESH]
  • |Receptors, Interleukin-6/genetics/immunology[MESH]
  • |SARS-CoV-2[MESH]
  • |Severity of Illness Index[MESH]
  • |Survival Analysis[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box